Landscape Capital Management L.L.C. Makes New Investment in MiniMed Group Inc $MMED

Landscape Capital Management L.L.C. acquired a new position in MiniMed Group Inc (NASDAQ:MMED – Free Report) in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund acquired 100,806 shares of the company’s stock, valued at approximately $1,963,000.

Other hedge funds also recently bought and sold shares of the company. Fifth Third Bancorp lifted its holdings in MiniMed Group by 420,970.0% in the third quarter. Fifth Third Bancorp now owns 252,642 shares of the company’s stock valued at $4,919,000 after acquiring an additional 252,582 shares during the period. Lisanti Capital Growth LLC bought a new stake in shares of MiniMed Group during the 3rd quarter valued at about $3,103,000. Ballast Asset Management LP bought a new stake in shares of MiniMed Group during the 3rd quarter valued at about $4,675,000. State of Wyoming purchased a new stake in shares of MiniMed Group during the 3rd quarter valued at about $167,000. Finally, Verdence Capital Advisors LLC purchased a new stake in shares of MiniMed Group during the 3rd quarter valued at about $861,000.

Analyst Ratings Changes

Several equities analysts have recently weighed in on the stock. Citigroup increased their price objective on shares of MiniMed Group from $23.00 to $26.00 and gave the stock a “buy” rating in a research note on Wednesday, September 2nd. UBS Group boosted their target price on shares of MiniMed Group from $25.00 to $28.00 and gave the company a “buy” rating in a research report on Wednesday, September 2nd. Wells Fargo & Company upped their target price on shares of MiniMed Group from $22.00 to $26.00 and gave the company an “overweight” rating in a report on Wednesday, September 2nd. Morgan Stanley increased their price target on shares of MiniMed Group from $19.00 to $21.00 and gave the stock an “overweight” rating in a research report on Thursday, September 3rd. Finally, Rothschild & Co Redburn initiated coverage on shares of MiniMed Group in a research note on Tuesday, October 13th. They set a “buy” rating and a $30.00 price target on the stock. Fourteen analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $24.12.

Get Our Latest Stock Report on MMED

MiniMed Group Stock Up 1.1%

NASDAQ MMED opened at $17.18 on Thursday. MiniMed Group Inc has a 52 week low of $10.65 and a 52 week high of $24.43. The company has a market capitalization of $4.83 billion and a P/E ratio of -25.05. The stock’s 50-day moving average price is $19.29 and its 200-day moving average price is $16.75.

About MiniMed Group

(Free Report)

MiniMed Group focuses on diabetes technology, developing products and services to help people manage insulin-dependent diabetes. Its offerings include insulin pumps, continuous glucose monitoring systems, infusion sets and software for tracking glucose and coordinating insulin delivery. The business is known for automated insulin-delivery systems that use glucose readings to help adjust insulin delivery, including products in the MiniMed 780G system line. Its technologies are intended for use by people with diabetes and the clinicians who support their care.

Further Reading

Want to see what other hedge funds are holding MMED? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for MiniMed Group Inc (NASDAQ:MMED – Free Report).

Institutional Ownership by Quarter for MiniMed Group (NASDAQ:MMED)

Receive News & Ratings for MiniMed Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MiniMed Group and related companies with MarketBeat.com's FREE daily email newsletter.